This company has been marked as potentially delisted and may not be actively trading.

Alpine Immune Sciences (ALPN) Competitors

ALPN vs. MANE, KLRA, GMTX, MOR, and ZYME

Should you be buying Alpine Immune Sciences stock or one of its competitors? The main competitors of Alpine Immune Sciences include MANE (MANE), Kailera Therapeutics (KLRA), Gemini Therapeutics (GMTX), MorphoSys (MOR), and Zymeworks (ZYME).

How does Alpine Immune Sciences compare to MANE?

Alpine Immune Sciences (NASDAQ:ALPN) and MANE (NYSE:MANE) are both mid-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

: MANE has a consensus price target of $83.33, suggesting a potential downside of 27.27%. Given MANE's stronger consensus rating and higher possible upside, analysts plainly believe MANE is more favorable than Alpine Immune Sciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alpine Immune Sciences
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
MANE
0 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.80
: 75.2% of Alpine Immune Sciences shares are held by institutional investors. 42.3% of Alpine Immune Sciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, MANE had 4 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 4 mentions for MANE and 0 mentions for Alpine Immune Sciences. MANE's average media sentiment score of 0.92 beat Alpine Immune Sciences' score of 0.00 indicating that MANE is being referred to more favorably in the news media.
Company Overall Sentiment
Alpine Immune Sciences Neutral
MANE Positive
: MANE has a net margin of 0.00% compared to Alpine Immune Sciences' net margin of -65.17%. MANE's return on equity of 0.00% beat Alpine Immune Sciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Alpine Immune Sciences -65.17% -14.86% -11.82%
MANE N/A N/A N/A
: MANE has lower revenue, but higher earnings than Alpine Immune Sciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpine Immune Sciences $56.52M 78.85 -$32.18M -$0.64 N/A
MANE N/A N/A N/A N/A N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpine Immune Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MANE	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Overall Sentiment
Alpine Immune Sciences	Neutral
MANE	Positive

Company	Net Margins	Return on Equity	Return on Assets
Alpine Immune Sciences	-65.17%	-14.86%	-11.82%
MANE	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpine Immune Sciences	$56.52M	78.85	-$32.18M	-$0.64	N/A
MANE	N/A	N/A	N/A	N/A	N/A

Summary

MANE beats Alpine Immune Sciences on 8 of the 11 factors compared between the two stocks.

How does Alpine Immune Sciences compare to Kailera Therapeutics?

Alpine Immune Sciences (NASDAQ:ALPN) and Kailera Therapeutics (NASDAQ:KLRA) are both mid-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

: Kailera Therapeutics has lower revenue, but higher earnings than Alpine Immune Sciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpine Immune Sciences $56.52M 78.85 -$32.18M -$0.64 N/A
Kailera Therapeutics N/A N/A N/A N/A N/A
: In the previous week, Kailera Therapeutics had 1 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 1 mentions for Kailera Therapeutics and 0 mentions for Alpine Immune Sciences. Alpine Immune Sciences' average media sentiment score of 0.00 equaled Kailera Therapeutics'average media sentiment score.
Company Overall Sentiment
Alpine Immune Sciences Neutral
Kailera Therapeutics Neutral
: Kailera Therapeutics has a net margin of 0.00% compared to Alpine Immune Sciences' net margin of -65.17%. Kailera Therapeutics' return on equity of 0.00% beat Alpine Immune Sciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Alpine Immune Sciences -65.17% -14.86% -11.82%
Kailera Therapeutics N/A N/A N/A
: 75.2% of Alpine Immune Sciences shares are held by institutional investors. 42.3% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpine Immune Sciences	$56.52M	78.85	-$32.18M	-$0.64	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Alpine Immune Sciences	Neutral
Kailera Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Alpine Immune Sciences	-65.17%	-14.86%	-11.82%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Kailera Therapeutics beats Alpine Immune Sciences on 4 of the 7 factors compared between the two stocks.

How does Alpine Immune Sciences compare to Gemini Therapeutics?

Alpine Immune Sciences (NASDAQ:ALPN) and Gemini Therapeutics (NASDAQ:GMTX) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

: Alpine Immune Sciences has higher revenue and earnings than Gemini Therapeutics. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alpine Immune Sciences $56.52M 78.85 -$32.18M -$0.64 N/A
Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A
: Alpine Immune Sciences has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
: In the previous week, Gemini Therapeutics had 1 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 1 mentions for Gemini Therapeutics and 0 mentions for Alpine Immune Sciences. Alpine Immune Sciences' average media sentiment score of 0.00 equaled Gemini Therapeutics'average media sentiment score.
Company Overall Sentiment
Alpine Immune Sciences Neutral
Gemini Therapeutics Neutral
: Gemini Therapeutics has a net margin of 0.00% compared to Alpine Immune Sciences' net margin of -65.17%. Alpine Immune Sciences' return on equity of -14.86% beat Gemini Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Alpine Immune Sciences -65.17% -14.86% -11.82%
Gemini Therapeutics N/A -38.78% -35.88%
: 75.2% of Alpine Immune Sciences shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 42.3% of Alpine Immune Sciences shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpine Immune Sciences	$56.52M	78.85	-$32.18M	-$0.64	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Company	Overall Sentiment
Alpine Immune Sciences	Neutral
Gemini Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Alpine Immune Sciences	-65.17%	-14.86%	-11.82%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Alpine Immune Sciences beats Gemini Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Alpine Immune Sciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Alpine Immune Sciences (NASDAQ:ALPN) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

: 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 75.2% of Alpine Immune Sciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 42.3% of Alpine Immune Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: In the previous week, MorphoSys' average media sentiment score of 0.00 equaled Alpine Immune Sciences'average media sentiment score.
Company Overall Sentiment
MorphoSys Neutral
Alpine Immune Sciences Neutral
: Alpine Immune Sciences has lower revenue, but higher earnings than MorphoSys. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
Alpine Immune Sciences $56.52M 78.85 -$32.18M -$0.64 N/A
: Alpine Immune Sciences has a net margin of -65.17% compared to MorphoSys' net margin of -226.79%. Alpine Immune Sciences' return on equity of -14.86% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
MorphoSys -226.79% -694.31% -22.55%
Alpine Immune Sciences -65.17% -14.86% -11.82%
: MorphoSys has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Company	Overall Sentiment
MorphoSys	Neutral
Alpine Immune Sciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Alpine Immune Sciences	$56.52M	78.85	-$32.18M	-$0.64	N/A

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Alpine Immune Sciences	-65.17%	-14.86%	-11.82%

Summary

Alpine Immune Sciences beats MorphoSys on 8 of the 11 factors compared between the two stocks.

How does Alpine Immune Sciences compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Alpine Immune Sciences (NASDAQ:ALPN) are both pharmaceutical preparations industry companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

: 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 75.2% of Alpine Immune Sciences shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 42.3% of Alpine Immune Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: In the previous week, Zymeworks had 3 more articles in the media than Alpine Immune Sciences. MarketBeat recorded 3 mentions for Zymeworks and 0 mentions for Alpine Immune Sciences. Zymeworks' average media sentiment score of 0.45 beat Alpine Immune Sciences' score of 0.00 indicating that Zymeworks is being referred to more favorably in the media.
Company Overall Sentiment
Zymeworks Neutral
Alpine Immune Sciences Neutral
: Alpine Immune Sciences has lower revenue, but higher earnings than Zymeworks. Alpine Immune Sciences is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zymeworks $105.96M 18.57 -$81.13M -$1.08 N/A
Alpine Immune Sciences $56.52M 78.85 -$32.18M -$0.64 N/A
: Zymeworks has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Alpine Immune Sciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
: Alpine Immune Sciences has a net margin of -65.17% compared to Zymeworks' net margin of -76.56%. Alpine Immune Sciences' return on equity of -14.86% beat Zymeworks' return on equity.
Company Net Margins Return on Equity Return on Assets
Zymeworks -76.56% -26.00% -20.57%
Alpine Immune Sciences -65.17% -14.86% -11.82%
: Zymeworks currently has a consensus price target of $37.89, indicating a potential upside of 42.01%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than Alpine Immune Sciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zymeworks
1 Sell rating(s)
1 Hold rating(s)

9 Buy rating(s)

2 Strong Buy rating(s)
2.92
Alpine Immune Sciences
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00

Company	Overall Sentiment
Zymeworks	Neutral
Alpine Immune Sciences	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	18.57	-$81.13M	-$1.08	N/A
Alpine Immune Sciences	$56.52M	78.85	-$32.18M	-$0.64	N/A

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-76.56%	-26.00%	-20.57%
Alpine Immune Sciences	-65.17%	-14.86%	-11.82%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Alpine Immune Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Zymeworks beats Alpine Immune Sciences on 10 of the 17 factors compared between the two stocks.

Get Alpine Immune Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALPN vs. The Competition

Export

Metric	Alpine Immune Sciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.46B	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	-101.52	1.71	29.25	27.07
Price / Sales	78.85	120.63	504.14	75.42
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	13.40	7.60	9.67	6.69
Net Income	-$32.18M	-$4.80M	$3.55B	$332.64M

Alpine Immune Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ALPN Alpine Immune Sciences	N/A	$64.97 flat	N/A	N/A	$4.46B	$56.52M	N/A	142
MANE MANE	N/A	$106.06 +2.9%	$83.33 -21.4%	N/A	$3.85B	N/A	N/A	19
KLRA Kailera Therapeutics	N/A	$24.76 +3.9%	N/A	N/A	$3.06B	N/A	N/A	145
GMTX Gemini Therapeutics	N/A	$67.26 -2.3%	N/A	N/A	$2.91B	N/A	N/A	30
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALPN) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alpine Immune Sciences (ALPN) Competitors

ALPN vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Alpine Immune Sciences compare to MANE?

Summary

How does Alpine Immune Sciences compare to Kailera Therapeutics?

Summary

How does Alpine Immune Sciences compare to Gemini Therapeutics?

Summary

How does Alpine Immune Sciences compare to MorphoSys?

Summary

How does Alpine Immune Sciences compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN vs. The Competition

Alpine Immune Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alpine Immune Sciences (ALPN) Competitors

ALPN vs. MANE, KLRA, GMTX, MOR, and ZYME

How does Alpine Immune Sciences compare to MANE?

Summary

How does Alpine Immune Sciences compare to Kailera Therapeutics?

Summary

How does Alpine Immune Sciences compare to Gemini Therapeutics?

Summary

How does Alpine Immune Sciences compare to MorphoSys?

Summary

How does Alpine Immune Sciences compare to Zymeworks?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN vs. The Competition

Alpine Immune Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools